Asthma

IEHP Celebrates 25 Years of "Doing the Right Thing"

Monday, September 27, 2021 - 10:21pm

RANCHO CUCAMONGA, Calif., Sept. 27, 2021 /PRNewswire/ -- Inland Empire Health Plan (IEHP) is celebrating 25 years of service this September.

Key Points: 
  • RANCHO CUCAMONGA, Calif., Sept. 27, 2021 /PRNewswire/ -- Inland Empire Health Plan (IEHP) is celebrating 25 years of service this September.
  • "In the last 25 years, we've had the incredible pleasure of connecting millions in our region to whole-person healthcare services," said Jarrod McNaughton, IEHP chief executive officer.
  • By 2000, IEHP had become one of the first Medi-Cal only health plans in California to receive "Commendable" NCQA Accreditation and ranked the ninth largest Medicaid Plan in the United States.
  • In addition to supporting transformative initiatives like CalAIM, IEHP is also working towards sustainable solutions to increase positive health outcomes of residents in the region.

Landos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual)

Monday, September 27, 2021 - 12:00pm

platform to develop novel therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will participate in the Truist Securities CEO Fireside Chat Series (Virtual).

Key Points: 
  • platform to develop novel therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will participate in the Truist Securities CEO Fireside Chat Series (Virtual).
  • The event will feature a one-one-one conversation led by Robyn Karnauskas, Ph.D., Managing Director and Senior Biotechnology Analyst, with audience participation, discussing all aspects of Landos Biopharma.
  • Investors interested in participating should contact their Truist Securities representative or, Marek Ciszewski, IR@LandosBiopharma.com .
  • Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism.

Box Pure Air's Highly Effective Plug And Play Solution Removes Air Quality Pollutants

Friday, September 24, 2021 - 3:15pm

As discussed in the 2010 study by National Institute for Respiratory Health of Mexico, "a substantial amount of respiratory illness stems from unclean indoor air."

Key Points: 
  • As discussed in the 2010 study by National Institute for Respiratory Health of Mexico, "a substantial amount of respiratory illness stems from unclean indoor air."
  • Microscopic particles in the air can cause minor pains (literally) like headaches, nausea and dizziness to full blown respiratory illness like asthma.
  • Besides causing reportable illness, poor indoor air quality has been proven to lead to lower test scores and decreased focus in students.
  • Box Pure Air has a highly effective plug and play solution to these problems for any size room within your home, school, or office.

Signature Kitchen Suite Selected As Exclusive Appliance Partner For Kips Bay Decorator Show House

Friday, September 24, 2021 - 2:00pm

DALLAS, Sept. 24, 2021 /PRNewswire/ -- Signature Kitchen Suite, the fast-growing luxury brand known for driving innovation in the built-in kitchen appliance market, has been named as the kitchen appliance partner for the 2021 Kips Bay Decorator Show House Dallas.

Key Points: 
  • DALLAS, Sept. 24, 2021 /PRNewswire/ -- Signature Kitchen Suite, the fast-growing luxury brand known for driving innovation in the built-in kitchen appliance market, has been named as the kitchen appliance partner for the 2021 Kips Bay Decorator Show House Dallas.
  • In addition to Signature Kitchen Suite products featured, the show home also includes award-winning laundry appliances from LG Electronics .
  • The Kips Bay Decorator Show House Dallas debuts to the public this week and will stay open through Oct. 24.
  • Since its inception, the Show House has raised over $25 million for the Kips Bay Boys & Girls Club.

CIIC and Trio Health Introduce the Creation of a Dynamic Rare Disease Patient Registry Platform

Thursday, September 23, 2021 - 3:47pm

IRVING, Texas, Sept. 23, 2021 /PRNewswire/ -- Trio Health (Trio), in partnership with the Consortium of Independent Immunology Clinics (CIIC), has launched the creation of a dynamic rare disease patient registry platform to transform drug development for allergy, asthma, and immunology patients.

Key Points: 
  • IRVING, Texas, Sept. 23, 2021 /PRNewswire/ -- Trio Health (Trio), in partnership with the Consortium of Independent Immunology Clinics (CIIC), has launched the creation of a dynamic rare disease patient registry platform to transform drug development for allergy, asthma, and immunology patients.
  • This tech-enabled patient registry platform is built to be smarter, faster, and better equipped than basic patient registries and big data, unlocking boundless possibilities for manufacturers.
  • Simply put, the real-time, agile, and bi-directional nature of this robust patient registry will provide insights that do not exist anywhere else today.
  • "The CIIC's new strategic partnership with Trio marks an exciting new chapter for the CIIC and our members," said CIIC President, Dr. Maeve O'Connor.

ENT and Allergy Associates, LLP To Relocate and Enhance Its Presence on the East Side of Manhattan

Thursday, September 23, 2021 - 11:00am

The move offers greater conveniences and comforts, as well as a more comprehensive and advanced menu of services to meet the growing patient population of Manhattan.

Key Points: 
  • The move offers greater conveniences and comforts, as well as a more comprehensive and advanced menu of services to meet the growing patient population of Manhattan.
  • The new facility boasts 12 ENT Exam Rooms, two Audio Booths, two Hearing Consultation rooms and an Allergy Injection room, along with Allergy Testing Rooms, and allows significant room for future growth and development.
  • "I look forward to the next chapter in the evolution of the East Side, Manhattan ENTA office.
  • ENTA has clinical alliances with Mount Sinai Hospital, Montefiore Medical Center, Northwell Health, and a partnership with the American Cancer Society.

Nicox Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial

Thursday, September 23, 2021 - 6:30am

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the results from its Mississippi Phase 2b clinical trial evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, against placebo in patients with acute exacerbations of blepharitis.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the results from its Mississippi Phase 2b clinical trial evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, against placebo in patients with acute exacerbations of blepharitis.
  • NCX 4251 was found to be safe and well-tolerated over 14 days treatment, with no serious adverse events, and all of the adverse events for the NCX 4251 treatment arm were mild.
  • Mississippi was a Phase 2b clinical trial, which recruited 224 patients at multiple clinical centers in the U.S., evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, versus placebo in patients with acute exacerbations of blepharitis.
  • Nicox and Ocumension Therapeutics have entered into an exclusive license agreement for the development and commercialization of NCX 4251 for blepharitis in the Chinese market.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets - ResearchAndMarkets.com

Wednesday, September 22, 2021 - 5:11pm

The "Global Obstructive Lung Disease Management Research Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Obstructive Lung Disease Management Research Report" report has been added to ResearchAndMarkets.com's offering.
  • The report provides a glimpse into the near future of respiratory disease treatment by highlighting newer therapeutics and advanced technologies that can address existing challenges in obstructive lung disease management.
  • Obstructive lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis are a huge burden on the global healthcare system.
  • What are the growth opportunities for companies developing new therapeutics and technologies for obstructive lung disease management?

Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Wednesday, September 22, 2021 - 1:00pm

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference, taking place September 27 30, 2021.

Key Points: 
  • Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference, taking place September 27 30, 2021.
  • Mr. Steel, Dr. Thomas and other members of Equilliums leadership team will be available for one-on-one meetings during the conference.
  • A live webcast of the presentation will be available under the Investors section of the Companys website at https://ir.equilliumbio.com/events-and-presentations .
  • Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

100% Chiropractic Expands National Footprint Into Arizona

Tuesday, September 21, 2021 - 2:00pm

SCOTTSDALE, Ariz., Sept. 21, 2021 (GLOBE NEWSWIRE) -- 100% Chiropractic today announced the official grand opening of its first clinic in the state of Arizona on Oct. 4, 2021.

Key Points: 
  • SCOTTSDALE, Ariz., Sept. 21, 2021 (GLOBE NEWSWIRE) -- 100% Chiropractic today announced the official grand opening of its first clinic in the state of Arizona on Oct. 4, 2021.
  • "Our explosive growth over the past three years demonstrates the increasing consumer demand for a more holistic, wellness-based approach toward chiropractic care," said Jason Helfrich, D.C., president and CEO of 100% Chiropractic.
  • "We could not be more excited about finally opening our practice to the public," said Jordan Jackson, D.C., clinic director of 100% Chiropractic - Paradise Valley.
  • 100% Chiropractic is a family of full-service wellness clinics that offer cutting-edge chiropractic care, massage therapy, and a full line of supreme-quality nutritional supplements through affordable cash plans and insurance acceptance.